SRT3.DE Sartorius AG (preference shares) Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
00:49
Jan 08
Stephen Yiu CIO and Co-Founder, Blue Whale Growth Fund The David Lin Report
Biologics equipment benefits from AI drug discovery.
Within healthcare he is selective and only invests in biologics. He owns Danaher and Sartorius, which supply manufacturing equipment for biologics used by biotech companies. He believes AI will accelerate drug discovery, and over about 10 years personalized drugs will grow versus chemical/synthetic drugs; the sector has lagged but should do well.
MED

About SRT3.DE Investor Commentary

Across the available history and selected sources, Buzzberg tracks SRT3.DE (Sartorius AG (preference shares)) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Stephen Yiu.